Avacta Group PLC (AVCT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -93.806x

Based on the latest financial reports, Avacta Group PLC (AVCT) has a cash flow conversion efficiency ratio of -93.806x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-13.51 Million ≈ $-1.64K USD) by net assets (GBX144.00K ≈ $17.52 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Avacta Group PLC market cap and net worth for the company's overall valuation and market capitalisation.

Avacta Group PLC - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how Avacta Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Avacta Group PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Avacta Group PLC ranked by their cash flow conversion efficiency. See how well can Avacta Group PLC service its debt to evaluate how effectively operating cash flow covers total debt obligations.

Company Cash Flow Conversion Efficiency
RareX Limited
F:CK1
-0.102x
Mears Group plc
LSE:MER
0.354x
Rare Earth Magnesium Technology Group Holdings Limited
STU:GPS
0.016x
Sequoia Financial Group Ltd
AU:SEQ
0.030x
Golden Sky Minerals Corp
V:AUEN
0.777x
Rincon Resources Ltd
AU:RCR
-0.029x
VVC Exploration Corp.
V:VVC
-0.017x
Mountview Estates PLC
LSE:MTVW
0.048x

Annual Cash Flow Conversion Efficiency for Avacta Group PLC (2001–2024)

The table below shows the annual cash flow conversion efficiency of Avacta Group PLC from 2001 to 2024. View current stock price of Avacta Group PLC for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX9.28 Million
≈ $1.13K
GBX-23.60 Million
≈ $-2.87K
-2.543x -272.78%
2023-12-31 GBX21.80 Million
≈ $2.65K
GBX-14.87 Million
≈ $-1.81K
-0.682x +23.47%
2022-12-31 GBX18.44 Million
≈ $2.24K
GBX-16.43 Million
≈ $-2.00K
-0.891x -79.15%
2021-12-31 GBX41.22 Million
≈ $5.02K
GBX-20.51 Million
≈ $-2.49K
-0.497x -189.48%
2020-12-31 GBX61.93 Million
≈ $7.53K
GBX-10.64 Million
≈ $-1.29K
-0.172x +32.71%
2018-07-31 GBX21.41 Million
≈ $2.61K
GBX-5.47 Million
≈ $-665.30
-0.255x -79.97%
2017-07-31 GBX29.89 Million
≈ $3.64K
GBX-4.24 Million
≈ $-516.01
-0.142x -20.19%
2016-07-31 GBX35.86 Million
≈ $4.36K
GBX-4.23 Million
≈ $-515.03
-0.118x +10.19%
2015-07-31 GBX19.13 Million
≈ $2.33K
GBX-2.52 Million
≈ $-306.00
-0.131x -352.36%
2014-07-31 GBX28.84 Million
≈ $3.51K
GBX-838.00K
≈ $-101.96
-0.029x +67.18%
2013-07-31 GBX15.55 Million
≈ $1.89K
GBX-1.38 Million
≈ $-167.54
-0.089x -111.16%
2012-07-31 GBX16.96 Million
≈ $2.06K
GBX-711.00K
≈ $-86.51
-0.042x +19.54%
2011-07-31 GBX11.44 Million
≈ $1.39K
GBX-596.00K
≈ $-72.52
-0.052x +70.16%
2010-07-31 GBX9.97 Million
≈ $1.21K
GBX-1.74 Million
≈ $-211.83
-0.175x +48.24%
2009-07-31 GBX8.30 Million
≈ $1.01K
GBX-2.80 Million
≈ $-340.56
-0.337x -26.84%
2008-07-31 GBX4.87 Million
≈ $592.42
GBX-1.29 Million
≈ $-157.56
-0.266x +44.06%
2007-07-31 GBX2.63 Million
≈ $319.87
GBX-1.25 Million
≈ $-152.09
-0.475x +95.21%
2006-04-30 GBX14.00K
≈ $1.70
GBX-139.00K
≈ $-16.91
-9.929x -148.21%
2005-04-30 GBX21.00K
≈ $2.56
GBX-84.00K
≈ $-10.22
-4.000x -916.22%
2004-04-30 GBX1.03 Million
≈ $125.81
GBX-407.00K
≈ $-49.52
-0.394x -315.55%
2003-04-30 GBX-230.00K
≈ $-27.98
GBX-42.00K
≈ $-5.11
0.183x -8.87%
2002-04-30 GBX-529.00K
≈ $-64.36
GBX-106.00K
≈ $-12.90
0.200x -47.29%
2001-04-30 GBX-363.00K
≈ $-44.17
GBX-138.00K
≈ $-16.79
0.380x --

About Avacta Group PLC

LSE:AVCT UK Biotechnology
Market Cap
$4.15 Million
GBX34.14 Billion GBX
Market Cap Rank
#29035 Global
#516 in UK
Share Price
GBX78.00
Change (1 day)
+2.63%
52-Week Range
GBX49.50 - GBX89.00
All Time High
GBX274.91
About

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more